Epirubucin, cisplatin, and continuous infusion 5‐fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An italian group for the study of digestive tract cancer (GISCAD) report

Background. A Phase II confirmatory multicenter trial was performed to evaluate a combination of epirubicin, cisplatin, and continuous infusion 5‐fluorouracil (ECF) in treating patients with advanced gastric cancer.

[1]  F. di Costanzo,et al.  Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Hickish,et al.  A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Talbot,et al.  Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Pichlmayr,et al.  Strategies in the surgical treatment of gastric carcinoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  C. Taat,et al.  Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: an effective regimen? , 1994, European journal of cancer.

[6]  D. Amadori,et al.  Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. D. De Braud,et al.  Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. , 1994, European journal of cancer.

[8]  D. Cunningham,et al.  Chemotherapy of carcinoma of the stomach. , 1993, Cancer treatment reviews.

[9]  Schedule‐dependent inhibition of thymidylate synthase by 5‐fluorouracil in gastric cancer , 1992, Cancer.

[10]  C. Lightdale,et al.  FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Mayer,et al.  Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Wampler,et al.  A prospective randomized comparison of protracted infusional 5‐fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid‐atlantic oncology program study , 1991, Cancer.

[14]  C. McConkey,et al.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. , 1990, British Journal of Cancer.

[15]  H. Wilke,et al.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Ausman,et al.  Continuous 5‐Fluorouracil Infusion in Advanced Gastric Carcinoma , 1988, American journal of clinical oncology.

[18]  D. Priest,et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  O. Dalesio,et al.  An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  O. Dalesio,et al.  cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. , 1985, European journal of cancer & clinical oncology.

[21]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[22]  F. Cavalli,et al.  A phase II study of cisplatin in advanced gastric cancer. , 1983, European journal of cancer & clinical oncology.

[23]  A. Lacave,et al.  Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. , 1983, American journal of clinical oncology.

[24]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[25]  I. Cohn,et al.  Adenocarcinoma of the stomach: Review of 1,497 cases , 1978, Cancer.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .